Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pilot Shows Single Drug Development Plan Can Meet Both Regulator And HTA Needs

This article was originally published in SRA

Executive Summary

The EU's pilot exercise in offering drug developers parallel regulatory and health technology assessment (HTA) advice has shown that in most cases a single trial design or drug development plan can be agreed that meets the requirements of the two parties without blurring their respective remits, says a new report from the European Medicines Agency1.

You may also be interested in...



Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs

The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.

UK To Seek Only Limited Regulatory Alignment With EU

Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.

‘No Unified Patent Court For Us’, Says UK Government

The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.

UsernamePublicRestriction

Register

PS118604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel